BeOne Medicines ONC
BeOne Medicines Ltd. · Nasdaq · Pharmaceutical Preparations
$373.36+2.00%close on Oct. 28, 2026 · volume 277K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 13, 2026 | Xiaodong Wang director | Sold 10b5-1 plan | 31,027 | $350.99 $349.56-$353.24 | $10.89 million |
| Sept. 30, 2026 | Chan Henry Lee SVP, General Counsel | Sold 10b5-1 plan | 1,115 | $375.00 | $418,125 |
| Sept. 28, 2026 | Xiaodong Wang director | Sold 10b5-1 plan | 31,028 | $364.79 $356.97-$367.23 | $11.32 million |
| Sept. 8, 2026 | Xiaodong Wang director | Sold 10b5-1 plan | 38,287 | $349.10 $345.38-$351.25 | $13.37 million |
| Sept. 1, 2026 | Titus B. Ball Principal Accounting Officer | Sold | 132 | $355.86 | $46,974 |
| Aug. 25, 2026 | Xiaobin Wu President and COO | Sold 10b5-1 plan | 280 | $380.00 | $106,400 |
| Aug. 12, 2026 | John Oyler Chief Executive Officer, director | Sold 10b5-1 plan | 54,892 | $358.15 $354.71-$359.12 | $19.66 million |
| Aug. 11, 2026 | Chan Henry Lee SVP, General Counsel | Sold 10b5-1 plan | 2,666 | $360.00 | $959,760 |
| Aug. 11, 2026 | John Oyler Chief Executive Officer, director | Sold 10b5-1 plan | 70,907 | $361.90 $359.32-$367.00 | $25.66 million |
| Aug. 10, 2026 | John Oyler Chief Executive Officer, director | Sold 10b5-1 plan | 115,011 | $357.87 $350.00-$360.63 | $41.16 million |
| Aug. 3, 2026 | Aaron Rosenberg Chief Financial Officer | Sold | 1,157 | $312.72 | $361,811 |
| July 30, 2026 | Chan Henry Lee SVP, General Counsel | Sold | 1,044 | $323.69 | $337,932 |
Latest 12 of 13. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.